Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- PIONEER 5 (NCT02827708)
- Testing
- semaglutide
- Where
- 117 sites in United States, Denmark and 6 more
- Volunteers
- 324 people
- Sponsor
- Novo Nordisk A/S
Diabetic Nepheopathy
Role of Renal Duplex Resistive Index (RRI) and Pulsatility Index (PI) in Assessment of Early Renal Microvascular Changes in Diabetic Patient
Diabetes mellitus (DM) is a globally prevalent metabolic disorder with an escalating burden on renal health. Diabetic kidney disease (DKD) represents the leading cause of end-stage renal disease (ESRD) worldwide, affecting…
- Trial name
- NCT07864740
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- NCT01620489
- Testing
- liraglutide
- Where
- 97 sites in United States, France and 4 more
- Volunteers
- 279 people
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity; Type 2 Diabetes
A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.
- Trial name
- NCT06435676
- Testing
- HRS9531
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)
To determine the pharmacokinetic properties, safety and tolerability of single/multiple oral administration of Gemigliptin and Food effect in healthy Chinese subjects.
- Trial name
- NCT03864432
- Testing
- Gemigliptin 25mg, Gemigliptin 50mg, Gemigliptin 100mg
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
- Trial name
- SUSTAIN 7 (NCT02648204)
- Testing
- semaglutide, Dulaglutide
- Where
- 209 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,201 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and…
- Trial name
- NCT06483243
- Testing
- Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Periodontitis, Type 2 Diabetes
Diabetes and Periodontal Therapy Trial
The primary aim of the study is to determine if non-surgical periodontal therapy (scaling and root planing and supportive periodontal therapy) is efficacious compared to delayed therapy in reducing elevated glycosylated…
- Trial name
- DPTT (NCT00997178)
- Testing
- Non-surgical periodontal therapy, Delayed non-surgical periodontal therapy
- Where
- 8 sites in United States
- Volunteers
- 514 people
- Sponsor
- Stony Brook University
Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT06108076
- Testing
- Ketone Monoester (KE)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 2
A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes
The purpose of this two-part study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT02588950
- Testing
- U-500R
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes
The aim of the study is to improve clinical outcomes for patients with type 2 diabetes by limiting the burden associated with insulin treatment.
- Trial name
- NCT04582435
- Testing
- Insulin Icodec
- Where
- Austria
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- NCT01572740
- Testing
- liraglutide, insulin
- Where
- 23 sites in Japan
- Volunteers
- 257 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Relative Bioavailability Study of HRS9531 in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.
- Trial name
- NCT05893576
- Testing
- HRS9531
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 1
Evaluation of the Hypoglycaemia Notification Device Hyposafe H02
To evaluate the technical performance of the hyposafe H02 during everyday activities and during insulin-induced hypoglycaemia, in addition to safety issues associated with the implantation and use of the hyposafe H02 in subjects…
- Trial name
- NCT02925676
- Testing
- hyposafe H02
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- UNEEG Medical A/S
Obese, Sleep Apnea, Obstructive
Nutritional Rehabilitation and Sleep Apnea in the Obese
In obese patients, the prevalence of obstructive sleep apnea (OSA) is around 40% in men and 30% in women. Weight loss after bariatric surgery significantly improves OSA, with 75% of patients having a reduction in OSA severity or…
- Trial name
- DIETSLEEP (NCT03857191)
- Testing
- Nutritional psychocomportemental rehabilitation
- Where
- France
- Volunteers
- 396 people
- Sponsor
- University Hospital, Grenoble
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing…
- Trial name
- BEGIN™ (NCT01068665)
- Testing
- insulin degludec, insulin glargine
- Where
- 116 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart
Primary Objective: To assess the effect of insulin glulisine on the post-prandial plasma glucose excursion during the first hour after a standard meal in comparison to insulin aspart in obese subjects with type 2 diabetes.
- Trial name
- NCT01159353
- Testing
- Insulin glulisine, Insulin aspart
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Sanofi
Type 2 Diabetes
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.
- Trial name
- NCT03771781
- Testing
- Empagliflozin Tablets, Empagliflozin Tab 25 MG
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine)…
- Trial name
- NCT02981966
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.